Tandem Diabetes Care Inc (TNDM) concluded trading on Thursday at a closing price of $21.75, with 12.51 million shares of worth about $272.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.90% during that period and on February 27, 2025 the price saw a loss of about -35.25%. Currently the company’s common shares owned by public are about 66.26M shares, out of which, 65.17M shares are available for trading.
Stock saw a price change of -32.29% in past 5 days and over the past one month there was a price change of -40.25%. Year-to-date (YTD), TNDM shares are showing a performance of -39.62% which decreased to -24.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $25.78 but also hit the highest price of $53.69 during that period. The average intraday trading volume for Tandem Diabetes Care Inc shares is 1.08 million. The stock is currently trading -35.32% below its 20-day simple moving average (SMA20), while that difference is down -37.81% for SMA50 and it goes to -44.21% lower than SMA200.
Tandem Diabetes Care Inc (NASDAQ: TNDM) currently have 66.26M outstanding shares and institutions hold larger chunk of about 113.30% of that.
The stock has a current market capitalization of $1.43B and its 3Y-monthly beta is at 1.40. It has posted earnings per share of -$1.47 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 1.80. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TNDM, volatility over the week remained 8.90% while standing at 5.12% over the month.
Stock’s fiscal year EPS is expected to rise by 16.74% while it is estimated to increase by 43.99% in next year. EPS is likely to grow at an annualized rate of 42.55% for next 5-years, compared to annual growth of -28.23% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 02, 2024 offering an Overweight rating for the stock and assigned a target price of $45 to it. Coverage by Bernstein stated Tandem Diabetes Care Inc (TNDM) stock as an Outperform in their note to investors on November 06, 2024, suggesting a price target of $42 for the stock. On October 04, 2024, Goldman Initiated their recommendations, while on October 02, 2024, RBC Capital Mkts Initiated their ratings for the stock with a price target of $65. Stock get an Equal-weight rating from Morgan Stanley on August 22, 2024.
